BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its stake in Zoetis Inc. (NYSE:ZTS) by 0.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 449,029 shares of the company’s stock after acquiring an additional 2,155 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.09% of Zoetis worth $28,630,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bbva Compass Bancshares Inc. grew its holdings in Zoetis by 4.9% during the second quarter. Bbva Compass Bancshares Inc. now owns 6,029 shares of the company’s stock worth $376,000 after purchasing an additional 283 shares during the period. Rothschild Asset Management Inc. grew its holdings in Zoetis by 7.4% during the second quarter. Rothschild Asset Management Inc. now owns 15,821 shares of the company’s stock worth $987,000 after purchasing an additional 1,095 shares during the period. Daiwa Securities Group Inc. grew its holdings in Zoetis by 15.6% during the second quarter. Daiwa Securities Group Inc. now owns 14,850 shares of the company’s stock worth $926,000 after purchasing an additional 2,000 shares during the period. First Manhattan Co. grew its holdings in Zoetis by 1.1% during the second quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock worth $567,000 after purchasing an additional 99 shares during the period. Finally, IFP Advisors Inc grew its holdings in Zoetis by 9.3% during the second quarter. IFP Advisors Inc now owns 17,838 shares of the company’s stock worth $1,113,000 after purchasing an additional 1,522 shares during the period. Institutional investors own 93.33% of the company’s stock.

Shares of Zoetis Inc. (ZTS) traded down $0.17 during mid-day trading on Wednesday, reaching $70.85. 2,261,500 shares of the company’s stock traded hands, compared to its average volume of 2,777,907. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The firm has a market capitalization of $34,607.21, a P/E ratio of 32.58, a PEG ratio of 2.13 and a beta of 1.06. Zoetis Inc. has a 1 year low of $49.55 and a 1 year high of $72.79.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period last year, the business posted $0.52 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. research analysts forecast that Zoetis Inc. will post 2.37 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were given a $0.105 dividend. The ex-dividend date of this dividend was Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.59%. Zoetis’s payout ratio is 22.11%.

A number of research firms recently commented on ZTS. Morgan Stanley upgraded Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target for the company in a report on Wednesday, November 29th. UBS restated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Cowen set a $80.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. Jefferies Group restated a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. Finally, BMO Capital Markets raised their price objective on shares of Zoetis from $65.00 to $70.00 and gave the stock a “market perform” rating in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $68.24.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/06/british-columbia-investment-management-corp-has-28-63-million-stake-in-zoetis-inc-zts.html.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.